Specialty Pharmacy

The anticipated action date for drug that treats moderate-to-severe active ulcerative colitis is set for March 2018.

PrEP has been found to be effective in preventing HIV in high-risk populations.

Neratinib, a kinase inhibitor, is indicated to follow therapy with trastuzumab to prevent breast cancer recurrence.

Scientists identify several new variants that affect the risk of lung cancer development.

Romosozumab is being investigated to treat postmenopausal women with osteoporosis.

Top news of the day from across the health care landscape.

Trastuzumab is indicated as an adjuvant therapy for HER2-positive breast cancer, along with metastatic breast and gastric cancers.

New report provides insight into patient awareness and attitudes towards biosimilars.

Findings point towards an HIV vaccine that stimulates the production of these antibodies.

Mice fed a tomato-rich diet experienced a 50% reduction in tumors.

Certain biomarkers influence outcomes in breast cancer patients treated with palbociclib.

Top news of the day from across the health care landscape.

Investigators aim to determine whether Zika virus interferes with antiretroviral drugs that prevent mother-to-child transmission of HIV.

Biosimilars have the potential to achieve billions in savings, but significant challenges remain.

Report finds socioeconomic factors that increase vulnerability to HIV.

Tremfya is the first and only approved biologic that selectively blocks the interleukin-23 protein.

A look at last week's top stories in the world of pharmacy.

Tremfya found to achieve significantly clearer skin in moderate to severe plaque psoriasis.

Voluntary medical male circumcision may help to reduce the spread of HIV.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Emicizumab is administered subcutaneously only once per week compared with clotting factors administered intravenously 3 times per week.

Selective oral immunomodulator plus tenofovir alafenamide (Vemlidy) seeks functional cure in chronic HBV.

Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how recently proposed transparency legislation may affect specialty pharmacies.

CTL019 is a chimeric antigen receptor T cell therapy.

Top news of the day from across the health care landscape.

Increasingly, individuals with HIV also have comorbid conditions, such as cardiovascular disease, hypertension, and diabetes.

The once-daily drug contains bictegravir and emtricitabine/tenofovir to treat adults with HIV-1.